These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 30830484)

  • 1. Untargeted metabolomics analysis of the upper respiratory tract of ferrets following influenza A virus infection and oseltamivir treatment.
    Beale DJ; Oh DY; Karpe AV; Tai C; Dunn MS; Tilmanis D; Palombo EA; Hurt AC
    Metabolomics; 2019 Mar; 15(3):33. PubMed ID: 30830484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuraminidase Mutations Conferring Resistance to Oseltamivir in Influenza A(H7N9) Viruses.
    Marjuki H; Mishin VP; Chesnokov AP; De La Cruz JA; Davis CT; Villanueva JM; Fry AM; Gubareva LV
    J Virol; 2015 May; 89(10):5419-26. PubMed ID: 25740997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model.
    Hurt AC; Lowther S; Middleton D; Barr IG
    Antiviral Res; 2010 Sep; 87(3):361-6. PubMed ID: 20603155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus.
    Govorkova EA; Ilyushina NA; Boltz DA; Douglas A; Yilmaz N; Webster RG
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1414-24. PubMed ID: 17296744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low dose influenza virus challenge in the ferret leads to increased virus shedding and greater sensitivity to oseltamivir.
    Marriott AC; Dove BK; Whittaker CJ; Bruce C; Ryan KA; Bean TJ; Rayner E; Pearson G; Taylor I; Dowall S; Plank J; Newman E; Barclay WS; Dimmock NJ; Easton AJ; Hallis B; Silman NJ; Carroll MW
    PLoS One; 2014; 9(4):e94090. PubMed ID: 24709834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel video tracking method to evaluate the effect of influenza infection and antiviral treatment on ferret activity.
    Oh DY; Barr IG; Hurt AC
    PLoS One; 2015; 10(3):e0118780. PubMed ID: 25738900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets.
    Herlocher ML; Truscon R; Elias S; Yen HL; Roberts NA; Ohmit SE; Monto AS
    J Infect Dis; 2004 Nov; 190(9):1627-30. PubMed ID: 15478068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oseltamivir inhibits influenza virus replication and transmission following ocular-only aerosol inoculation of ferrets.
    Belser JA; Maines TR; Creager HM; Katz JM; Tumpey TM
    Virology; 2015 Oct; 484():305-312. PubMed ID: 26142497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oseltamivir prophylactic regimens prevent H5N1 influenza morbidity and mortality in a ferret model.
    Boltz DA; Rehg JE; McClaren J; Webster RG; Govorkova EA
    J Infect Dis; 2008 May; 197(9):1315-23. PubMed ID: 18422444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of Neuraminidase Activity Exacerbates Disease in 2009 Pandemic Influenza Virus-Infected Mice.
    Ranadheera C; Hagan MW; Leung A; Collignon B; Cutts T; Theriault S; Embury-Hyatt C; Kobasa D
    J Virol; 2016 Nov; 90(21):9931-9941. PubMed ID: 27558428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo.
    Ives JA; Carr JA; Mendel DB; Tai CY; Lambkin R; Kelly L; Oxford JS; Hayden FG; Roberts NA
    Antiviral Res; 2002 Aug; 55(2):307-17. PubMed ID: 12103431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo.
    Carr J; Ives J; Kelly L; Lambkin R; Oxford J; Mendel D; Tai L; Roberts N
    Antiviral Res; 2002 May; 54(2):79-88. PubMed ID: 12062393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced airborne transmission of oseltamivir-resistant pandemic A/H1N1 virus in ferrets.
    Hamelin ME; Baz M; Bouhy X; Beaulieu E; Dubé K; Mallett C; Boivin G
    Antivir Ther; 2011; 16(5):775-9. PubMed ID: 21817200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mammalian pathogenesis of oseltamivir-resistant pandemic (H1N1) 2009 influenza virus isolated in South Korea.
    Kwon D; Shin K; Kim SJ; Lee JY; Kang C
    Virus Res; 2014 Jun; 185():41-6. PubMed ID: 24657788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylaxis of ferrets with nitazoxanide and oseltamivir combinations is more effective at reducing the impact of influenza a virus infection compared to oseltamivir monotherapy.
    Mifsud EJ; Tilmanis D; Oh DY; Ming-Kay Tai C; Rossignol JF; Hurt AC
    Antiviral Res; 2020 Apr; 176():104751. PubMed ID: 32088248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the neuraminidase mutation H274Y conferring resistance to oseltamivir on the replicative capacity and virulence of old and recent human influenza A(H1N1) viruses.
    Baz M; Abed Y; Simon P; Hamelin ME; Boivin G
    J Infect Dis; 2010 Mar; 201(5):740-5. PubMed ID: 20100088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interactions of oseltamivir-sensitive and -resistant highly pathogenic H5N1 influenza viruses in a ferret model.
    Govorkova EA; Ilyushina NA; Marathe BM; McClaren JL; Webster RG
    Influenza Other Respir Viruses; 2011 May; 5(Suppl 1):90-3. PubMed ID: 21751467
    [No Abstract]   [Full Text] [Related]  

  • 18. The Hemagglutinin A Stem Antibody MEDI8852 Prevents and Controls Disease and Limits Transmission of Pandemic Influenza Viruses.
    Paules CI; Lakdawala S; McAuliffe JM; Paskel M; Vogel L; Kallewaard NL; Zhu Q; Subbarao K
    J Infect Dis; 2017 Aug; 216(3):356-365. PubMed ID: 28633457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oseltamivir Population Pharmacokinetics in the Ferret: Model Application for Pharmacokinetic/Pharmacodynamic Study Design.
    Reddy MB; Yang KH; Rao G; Rayner CR; Nie J; Pamulapati C; Marathe BM; Forrest A; Govorkova EA
    PLoS One; 2015; 10(10):e0138069. PubMed ID: 26460484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influenza A/H3N2 virus infection in immunocompromised ferrets and emergence of antiviral resistance.
    Roosenhoff R; van der Vries E; van der Linden A; van Amerongen G; Stittelaar KJ; Smits SL; Schutten M; Fouchier RAM
    PLoS One; 2018; 13(7):e0200849. PubMed ID: 30024940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.